GINS2 Promotes Osteosarcoma Tumorigenesis via STAT3/MYC Axis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• GINS2 (Go-Ichi-Ni-San related complex subunit 2) is overexpressed in various cancers.
• Its specific role and implications in osteosarcoma (OS) remain largely uncharacterized.
• Understanding GINS2's function in OS is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role and molecular mechanisms of GINS2 in osteosarcoma (OS).
• To determine the association between GINS2 expression and patient prognosis.
• To explore GINS2 as a potential therapeutic target in OS.

Main Methods:

• In vivo and in vitro experiments including cell line studies and xenograft tumor models.
• Affymetrix gene chip analysis and pathway analysis to identify affected signaling pathways.
• Liquid chromatography-mass spectrometry (LC-MS), Co-immunoprecipitation (CoIP), and rescue experiments to elucidate molecular mechanisms.

Main Results:

• GINS2 was found to be highly expressed in OS tissues and cell lines, correlating with poor patient outcomes.
• GINS2 knockdown inhibited OS cell growth and induced apoptosis in vitro, and suppressed tumor growth in vivo.
• GINS2 knockdown reduced the expression of targeted genes and attenuated the MYC signaling pathway activity.
• GINS2 promotes OS progression through the STAT3/MYC axis and is associated with tumor immunity.

Conclusions:

• GINS2 is a significant driver of osteosarcoma progression and is associated with adverse patient outcomes.
• Targeting GINS2, particularly through the STAT3/MYC axis, offers a promising therapeutic strategy for OS.
• GINS2 represents a potential immunotherapeutic target for osteosarcoma treatment.